Aastrom Biosciences, Inc. Granted Composition-Of-Matter Patent For Ixmyelocel-T In Australia

ANN ARBOR, Mich., Dec. 19, 2013 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded multicellular therapies for the treatment of severe chronic cardiovascular diseases, today announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.

Help employers find you! Check out all the jobs and post your resume.